SC
VTGN icon

Stempoint Capital’s VistaGen Therapeutics VTGN Stock Holding History

Stempoint Capital’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$58.2K Hold
616,749
– – 0.01% 78
2025
Q4 		$142K Sell
616,749
-1,871,936
-75% -$6.76M 0.02% 76
2025
Q3 		$7.75M Buy
2,488,685
+75,431
+3% +$225K 1.55% 20
2025
Q2 		$4.12M Buy
2,413,254
+46,700
+2% +$106K 1.32% 25
2025
Q1 		$5.11M Buy
2,366,554
+38,062
+2% +$108K 1.63% 25
2024
Q4 		$5.95M Buy
2,328,492
+481,700
+26% +$1.36M 1.48% 25
2024
Q3 		$4.9M Sell
1,846,792
-1,790
-0.1% -$6.11K 1.47% 22
2024
Q2 		$5.85M Hold
1,848,582
– – 1.72% 17
2024
Q1 		$9.29M Buy
1,848,582
+58,400
+3% +$281K 2.46% 14
2023
Q4 		$8.76M Buy
+1,790,182
New +$6.77M 2.34% 17

Other funds holding VTGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Stempoint Capital's VTGN Position: Q1 2026 in Review

Stempoint Capital held its VistaGen Therapeutics (VTGN) position steady in Q1 2026 at 616,749 shares worth $58.2K. The position accounts for 0.01% of the portfolio, ranked #78.

Stempoint Capital first reported a position in VTGN in Q4 2023 and has held it in 10 quarters since. The position peaked at $9.29M in Q1 2024. 56 funds tracked by Wall St. Rank hold VTGN as of Q1 2026.

  • Stempoint Capital held 616,749 shares of VistaGen Therapeutics worth $58.2K as of Q1 2026.
  • Stempoint Capital left its VistaGen Therapeutics share count unchanged in Q1 2026.
  • VistaGen Therapeutics made up 0.01% of Stempoint Capital's portfolio in Q1 2026, its #78 holding.
  • Stempoint Capital first reported a position in VistaGen Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • Stempoint Capital's VistaGen Therapeutics position peaked at $9.29M in Q1 2024.
  • 56 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2026.

Based on Stempoint Capital's 13F filing for Q1 2026, filed 15 May 2026.